Gallardo-Rincón D, Cantú-de-León D, Alanís-López P, Álvarez-Avitia MÁ, Bañuelos-Flores J, Herbert-Núñez GS, Oñate-Ocaña LF, Pérez-Montiel MD, Rodríguez-Trejo A, Ruvalcaba-Limón E, Serrano-Olvera A, Ortega-Rojo A, Cortés-Esteban P, Erazo-Valle A, Gerson-Cwilich R, De-la-Garza-Salazar J, Green-Renner D, León-Rodríguez E, Morales-Vásquez F, Poveda-Velasco A, Aguilar-Ponce JL, Alva-López LF, Alvarado-Aguilar S, Alvarado-Cabrero I, Aquino-Mendoza CA, Aranda-Flores CE, Bandera-Delgado A, Barragán-Curiel E, Barrón-Rodríguez P, Brom-Valladares R, Cabrera-Galeana PA, Calderillo-Ruiz G, Camacho-Gutiérrez S, Capdeville-García D, Cárdenas-Sánchez J, Carlón-Zárate E, Carrillo-Garibaldi Ó, Castorena-Roji G, Cervantes-Sánchez G, Coronel-Martínez JA, Chanona-Vilchis JG, Díaz-Hernández V, Escudero-de-los Ríos P, Garibay-Cerdenares O, Gómez-García E, Herrera-Montalvo LA, Hinojosa-García LM, Isla-Ortiz D, Jiménez-López J, Lavín-Lozano AJ, Limón-Rodríguez JA, López-Basave HN, López-García SC, Maffuz-Aziz A, Martínez-Cedillo J, Martínez-López DM, Medina-Castro JM, Melo-Martínez C, Méndez-Herrera C, Montalvo-Esquivel G, Morales-Palomares MÁ, Morán-Mendoza A, Morgan-Villela G, Mota-García A, Muñoz-González DE, Ochoa-Carrillo FJ, Pérez-Amador M, Recinos-Money E, Rivera-Rivera S, Robles FJU, Rojas-Castillo E, Rojas-Marín C, Salas-Gonzáles E, Sámano-Nateras L, Santibañez-Andrade M, Santillán-Gómez A, Silva-García A, Silva JA, Solorza-Luna G, Tabarez-Ortiz AR, Talamás-Rohana P, Tirado-Gómez LL, Torres-Lobatón A, Quijano-Castro F

Language: Spanish
References: 175
Page: 665-702
PDF size: 339.35 Kb.

ABSTRACT

Introduction. Ovarian cancer (OC) is the third most common gynecologic malignancy worldwide. Most of cases it is of epithelial origin. At the present time there is not a standardized screening method, which makes difficult the early diagnosis. The 5-year survival is 90% for early stages, however most cases present at advanced stages, which have a 5-year survival of only 5-20%. GICOM collaborative group, under the auspice of different institutions, have made the following consensus in order to make recommendations for the diagnosis and management regarding to this neoplasia. Material and methods. The following recommendations were made by independent professionals in the field of Gynecologic Oncology, questions and statements were based on a comprehensive and systematic review of literature. It took place in the context of a meeting of two days in which a debate was held. These statements are the conclusions reached by agreement of the participant members. Results. No screening method is recommended at the time for the detection of early lesions of ovarian cancer in general population. Staging is surgical, according to FIGO. In regards to the pre-surgery evaluation of the patient, it is recommended to perform chest radiography and CT scan of abdomen and pelvis with IV contrast. According to the histopathology of the tumor, in order to consider it as borderline, the minimum percentage of proliferative component must be 10% of tumor’s surface. The recommended standardized treatment includes primary surgery for diagnosis, staging and cytoreduction, followed by adjuvant chemotherapy. Surgery must be performed by an Oncologist Gynecologist or an Oncologist Surgeon because inadequate surgery performed by another specialist has been reported in 75% of cases. In regards to surgery, it is recommended to perform total omentectomy since subclinic metastasis have been documented in 10-30% of all cases, and systematic limphadenectomy, necessary to be able to obtain an adequate surgical staging. Fertility-sparing surgery will be performed in certain cases, the procedure should include a detailed inspection of the contralateral ovary and also negative for malignancy omentum and ovary biopsy. Until now, laparoscopy for diagnostic-staging surgery is not well known as a recommended method. The recommended chemotherapy is based on platin and taxanes for 6 cycles, except in Stage IA, IB and grade 1, which have a good prognosis. In advanced stages, primary cytoreduction is recommended as initial treatment. Minimal invasion surgery is not a recommended procedure for the treatment of advanced ovarian cancer. Radiotherapy can be used to palliate symptoms. Follow up of the patients every 2-4 months for 2 years, every 3-6 months for 3 years and anually after the 5th year is recommended. Evaluation of quality of life of the patient must be done periodically. Conclusions. In the present, there is not a standardized screening method. Diagnosis in early stages means a better survival. Standardized treatment includes primary surgery with the objective to perform an optimal cytoreduction followed by chemotherapy. Treatment must be individualized according to each patient. Radiotherapy can be indicated to palliate symptoms.

REFERENCES

1. Jemal A, Bray F, Center MM, et al. Global Cancer Statistics. Cancer J Clin 2011; 61: 69-90.

2. American Cancer Society. Cancer Facts and Figures 2008. Atlanta Ga. Am Cancer Soc 2008.

3. Reporte Histopatológico de Neoplasias Malignas 2003.

4. Berek J, Trope C, Vergote I. Surgery during chemotherapy and at relapse of ovarian cancer. Ann Oncol 1999; 10(Suppl. 1): 3-7.

5. Centers for Disease Control and Prevention US Cancer Statistics: 1999-2005. Cancer incidence and mortality data US Department of Health and Human Services. Accessed February, 26, 2009.

6. Armstrong D, Bundy B, Wentzel L, Huang H, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34-43.

7. Kurman R, Shih L. Pathogenesis of Ovarian Cancer: Lessons From Morphology and Molecular Biology and Their Clinical Implications. Int J Gynecol Pathol 2008; 27: 151-60.

8. Russo A, Calo V, Bruno L, Rizzo S, Bazan V, DiFede G. Hereditary ovarian cancer. Crit Rev Oncol Hematol 2009; 69: 28-44.

9. Hereditary Breast and Ovarian Cancer Syndrome. The University of Texas M. D. Anderson Cancer Center, Revised 09/15/09 Patient Education Office. Available from: http://www2.mdanderson.org/app/pe/index.cfm?pageName=opendoc&docid=2361 [Accessed on June, 2011].

10. Gruber S, Kohlmann W. The genetics of hereditary non-polyposis colorectal cancer. J Natl Compr Canc Netw 2003; 1: 137-44.

11. Chen LM, Karlan BY. Early detection and risk reduction for familial gynecologic cancers. Clin Obstet Gynecol 1998; 41(1): 200-14.

12. Whittemore AS. Characteristics relating to ovarian cancer risk: implications for prevention and detection. Gynecol Oncol 1994; 55(3, pt. 2): S15-S19.

13. Riman T, Dickman PW, Nilsson S, et al. Risk factors for invasive epithelial ovarian cancer: result from a Swedish case-control study. Am J Epidemio 2002; 156: 363-73.

14. Booth M, Beral V, Smith P. Risk factors for ovarian cancer: a case-control study. Br J Cancer 1989; 60: 592-8.

15. Risch H, Marrett L, Howe G. Parity, Contraception, Infertility, and the Risk of Epithelial Ovarian Cancer. Am J Epidemiol 1994; 140(7): 585-97.

16. Mahdavi A, Pejovic T, Nezhat F. Induction of ovulation and ovarian cancer: a critical review of the literature. Fertil Steril 2006; 85: 819-26.

17. Bristow BE, Karlan BY. Ovulation induction, infertility and ovarian cancer risk. Fertil Steril 1996; 66: 499-507.

18. Fairfield K, Willett W, Rosner B, Manson J, Speizer F, Hankinson S. Obesity, Weight Gain, and Ovarian Cancer. Obstet Gynecol 2002; 100(2): 288-96.

19. Jordan S, Whitteman D, Purdie D, Green A, Webb P. Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol 2006; 103: 1122-9.

20. Clarke-Pearson D. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009; 361(2): 170-7.

21. Pavlik E, DePriest P, Gallion H, Ueland F, Reedy M, Kryscio R, et al. Ovarian volume related to age. Gynecol Oncol 2000; 77: 410-2.

22. DePriest P, Varner E, Powell J, et al. The efficacy of a sonographic morphology index in identifying ovarian cancer: a multiinstitutional investigation. Gynecol Oncol 1994; 55: 174-8.

23. Jacobs et al. A risk of malignacy index incorporating Ca125, ultrasound and menopausal status for the acurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990; 97: 922-9.

24. Chen V, Ruiz B, Killeen J, Coté T, Wu X, Correa C. Pathology and classification of ovarian tumors. Cancer 2003; 97(10, Suppl.): 2631-42.

25. Kathleen R. Cho Ovarian Cancer Update: Lessons from Morphology, Molecules and Mice. Arch Pathol Lab Med 2009; 133: 1775-81.

26. Malpica A. Grading of ovarian cancer. Int J Gynecol Pathol 2008; 27: 175-81.

27. Kline R, Wharton J, Atkinson E, et al. Endometrioid carcinoma of the ovary: retrospective review of 145 cases. Gynecol Oncol 1990; 39: 337-46.

28. Gitsch G, Kohlberger P, Steiner A, Neumeister B, Breitenecker G. Expression of cytokeratins in granulosa cell tumors and ovarian carcinomas. Arch Gynecol Obstet 1992; 251(4): 193-7.

29. Yoshida S, Furukawa N, Haruta S, Tanase Y, Kanayama S, Noguchi T, et al. Expression Profiles of Genes Involved in Poor Prognosis of Epithelial Ovarian Carcinoma A Review. Int J Gynecol Cancer 2009; 19(6): 992-7.

30. Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 2004; 22(23): 4700-10.

31. Sorrentino A, Liu C, Addario A, Peschle C, Scambia G, Ferlini C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 2008; 111: 478-86.

32. Yang H, Kong W, He L, Zhao J, O’Donnell J, Wang J, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008; 68: 425-33.

33. Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Chan G, et al. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009; 113: 249–55.

34. Eitan R, Kushnir M, Lithwick-Yanai G, David MB, Hoshen M, Glezerman M, et al. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol Oncol 2009; 114(2): 253-9.

35. Vella N, Aiello M, Russo AE, Scalisi A, Spandidos DA, Toffoli G, et al. Genetic profiling and ovarian cancer therapy (Review). Mol Med Report 2011.

36. Bristow R, Tomacruz R, Armstrong D, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma During de platinum era: A metaanalisis. J Clin Oncol 2002; 20: 1248-54.

37. Poveda A, Casado H, Gallardo R, et al. Treatment guidelines in ovarian cancer. Clin transl Oncol 2007; 9: 308-16.

38. Federación Internacional de Ginecología y Obstetricia, 1986.

39. Buchsbaum HJ, Brady MF, Delgado G, et al. Surgical staging of Ovarian carcinoma: A GOG study. Sur Gynecol Obstet 1989; 169: 226-32.

40. Leblanc E, Querleu D, Narducci F, et al. Surgical staging of early invasive epitelial ovarian tumors. Semin Surg Oncol 2000; 19: 36-41.

41. Trimbos J, Vergote I, Bolis G, et al. Impact of adyuvant chemotherapy and surgical stanging in early stage ovarian carcinoma: EORT-Trial. J. Natl cancer inst 2003; 95: 113-25.

42. Pommel C, Jeyarahab A, Oram D, et al. Cytoreductive surgery in ovarian cancer. Cancer imaging 2007; 7: 210-5.

43. Chi D, Abu-Rustum N, Sonoda Y, Ivy J, Rhee E, Moore K, et al. The safety an efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancer. Am J Obstet Gynecol 2005; 192(5): 1614-9.

44. Ghezz F, Cromi A, Uccella S, Bergamini V, Tomera S, Franchi M, et al. Laparoscopy versus laparotomy for surgical management of apparent early stage ovarian cancer. Gynecol Oncol 2007; 105(2): 409-13.

45. Park J, Kim D, Suh D, Kim J, Kim Y, Kim Y, et al. Comparison of laparoscopy an laparotomy in surgical stanging of early- stage Ovarian and fallopian tubal cancers. Ann Surg Oncol 2008; 15(7): 2012-9.

46. Medeiros L, Rosa D, Bozzetti M, Rosa M, Edelweiss M, Stein A, et al. Laparoscopy versus laparotomy FIGO stage I Ovarian cancer. Cochrane Database Syst Rev 2008; (4).

47. Morice P, Joulie F, Camatte S, et al. Lymph node involvement in epithelial ovarian cancer: Analysis of 276 pelvic an paraortic lymphadenectomies and surgical implications J. Am Coll Surg 2003; 197(2): 198-205.

48. Kim H, Ju W, Jee B, et al. Systematic lymphadenectomy for survival in epithelial ovarian cancer: a metaanalysis. Int J Gynecol Cancer 2010; 20(4): 520-8.

49. Angioli R, Plotti F, Palaia I, Calcagno M, Montera R, Cafà EV, Sereni MI, et al. Update on Lynphadenectomy in early and advanced ovarian cancer. Curr Opin Obstet Gyneco 2008; 20(1): 34-9.

50. Nelson B, Rosenfield A, Schwartz P. Preoperative abdominopelvic computed tomography prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 1993; 11: 166-72.

51. Ibeanu OA, Bristow RE. Predicting the outcome of cytoreductive surgery for advanced ovarian cancer: a review. Int J Gynecol Cancer 2010; 20: S1: S1-S11.

52. Roett M, Evans P. Ovarian Cancer: An Overview. Am Fam Physician 2009; 80(6): 609-16.

53. Verleye L, Ottevanger P, van der Graaf W, Reed N, Vergote I; Gynaecological Cancer Group (GCG) of European Organisation for Research and Treatment of Cancer (EORTC). EORTC- GCG process quality indicators for ovarian cancer surgery. Eur J Cancer 2009; 45(4): 517-26.

54. Eisenkop S, Spirtos NM, Ontag T, et al. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 1992; 47: 203-9.

55. Hoskins W, McGuire W, Brady M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994; 70: 974-80.

56. Bristow RE, Montz FJ, Lagasse LD, et al. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999; 72: 278-87.

57. Zang R, Zhang Z, Cai S, et al. Cytoreductive surgery for stage IV epithelial ovarian cancer. J Exp Clin Cancer Res 1999; 18: 449-54.

58. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 2009; 15; 115(6): 1234-44.

59. Vergote I, Coens C, De Rouck M. EORTC protocol 55971.Randomized Phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy in patients with Stage IIIc or IV epithelial ovarian carcinoma. 2006.

60. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363(10): 943-53.

61. Rose PG, Nerenstone S, Brady MF, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004; 24: 2489-97.

62. Greer B, Bundy B, Ozols R, et al. Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study. Gynecol Oncol 2005; 99: 71.

63. Obermair A, Sevelda P. Impact of second look laparotoy and secondary cytoreductive surgery at second look laparotomy in ovarian cancer patients. Acta Obstet Gynecol Scand 2001; 80: 432-6.

64. Pimentel A, Cervantes M. Quimioterapia en cáncer epitelial de ovario:revisión de la bibliografía. GAMO 2010; 9: 4.

65. McGuire W, Brady M, Ozols R. The Gynecologic Oncology Group experience in ovarian cancer. Ann Oncol 1999; 10 (S1): 29-34.

66. Muggia F, Braly P, Brady M, Sutton G, Niemann T, Lentz S, et al. Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2000; 18(1): 106.

67. Neijt J, Engelholm S, Tuxen M, Sørensen P, Hansen M, Sessa C, et al. Exploratory Phase III Study of Paclitaxel and Cisplatin Versus Paclitaxel and Carboplatin in Advanced Ovarian Cancer. J Clin Oncol 2000; 18(17): 3084-92.

68. Ozols R, Bundy B, Greer B, Fowler J, Clarke-Pearson D, Burger R, et al. Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2003; 21(17): 3194-200.

69. Bookman MA. GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel and carboplatin vs. combinations with gemcitabine, PEG-liposomal doxorubicin, or topotecan in patients with advanced-stage epithelial ovarian or primary peritonealcarcinoma. Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology; June 2–6, 2006; Atlanta, Ga. abstract 5002.

70. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374(9698): 1331-8.

71. A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865, IND #7921) Followed By Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Suboptimal Advanced Stage Epithelial Ovarian, Primary Peritoneal Cancer, or Fallopian Tube Cancer. Available from: http://clinicaltrials.gov/ct/show/NCT00262847

72. A randomised, two arm, multi-centre Gynaecologic Cancer InterGroup phase III trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in first line treatment of patients with epithelial ovarian cancer. Available from: http://www icon7trial.org/ [Accessed on June, 2011].

73. Phase III randomized study of adjunvant chemotherapy comprising carboplatin and paclitaxel wth versus without bevacizumab and/or secondary citoreduction surgery in patients with platinum-sensitive recurrent ovarian epithelial cancer, primary peritoneal cavity cancer, or Fallopian tube cancer. National Cancer Institute. Available from: http://cancer.gov/clinicaltrials/ search/view?cdrid=546714&version=healthprofesional [Accessed on June, 2011].

74. Aghajanian C, Finkler NJ, Rutherford T, Smith DA, Yi J, Parmar H, et al. OCEANS: A randomized, double-blinded, placebo- controlled phase III trial of chemotherapy with or without bavacizumab (BEV) in patients with platinum-sensitive recurrent ephitelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol 2011; 29(Suppl.): abstract LBA5007.

75. American Society of Clinical Oncology (ASCO) 2010 Annual Meeting: Abstract LBA1. Presented June 6, 2010.

76. Gallardo D, Cortés P. Quimioterapia Intraperitoneal en Cáncer de Ovario Epitelial. Cancerología 2007; S1: S61-S62.

77. Omura G, Gynecologic Oncology Group. Progress in gynecologic cancer research: the Gynecologic Oncologic Group experience. Semin Oncol 2008; 35(5): 507-21.

78. Liz Y Han, Kipps E, Stan K, et al. Current treatment and clinical trial in ovarian cancer. Expt Opin Investig Drugs 2010; 19(4): 521-34.

79. ICON I and EORTC. Action collaboratos. International collaborative ovarian neoplasma trial and adyuvant Chemo therapy in ovarian neoplasm trial. Two parallel randomized phase lll trials of adyuvant Chemotherapy in patients with early–stage ovarian carcinoma. J Natl Cancer Inst 2003; 95: 105-12.

80. Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart A, et al. International Collaborative Ovarian Neoplasm trial: a randomized trial of adyuvant chemotherapy in women with earlystage ovarian cancer. J Natl Cancer Inst 2003; 95(2): 125-32.

81. Bell J, Brady M, Young R, Lage J, Walker J, Look K, et al. Randomized phase lll trial of three versus six cycles of adyuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2006; 102(3): 432-9.

82. Fagotti A, Paris I, Grimolizzi F, Fanfani F, Vizzielli G, Naldini A, et al. Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: A pilot study. Gynecol Oncol 2009; 113(3): 335-40.

83. Bristow R, Chi D. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 2006; 103(3): 1070-6.

84. Milam M, Tao X, Coleman R, Harrell R, Bassett R, Dos Reis R. Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 2011; 21(1): 66-71.

85. Bast R, Feeenet M, Lazarus H, Nadler L, Colvin R. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68; 1331.

86. Jacobs I, Bast RC. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989; 4: 1-12.

87. National Comprehensive Cancer Network. Ovarian Cancer. NCCN Clinical Practice Guidelines in Oncology. V2, 2011. Available from: www.nccn.com

88. Zurawski V, Orjaseter H, Andersen A, Jellum E. Elevated serum CA125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer 1988; 42(5): 677-80.

89. Rustin G, Bast R, Kelloff G, Barrett J, Carter S, Nisen P, et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 2004; 10(11): 3919-26.

90. Rustin G, Nelstrop A, Tuxen M, Lambert H. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Themes Ovary Group Study. Ann Oncol 1996; 7(4): 361-64.

91. Rustin G, Marples M, Nelstrop A, Mahmoudi M, Meyer T. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 2001; 19(20): 4054-7.

92. Santillan A, Garg R, Zahurak M, Gardner G, Giuntoli R, Armstrong DK, et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol 2005; 23(36): 9338-43.

93. Markman M. Optimal management of recurrent ovarian cancer. Int J Gynecol Cancer 2009; 19(S2): S40-S43.

94. Gu P, Pan L, Wu S, Sun L, Huang G. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol 2009; 71(1): 164-74.

95. Ushijima K. Treatment for recurrent ovarian cancer-at first relapse. J Oncol 2010.

96. Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol 2004; 95(2): 273-90.

97. Sehouli J, Stengel D, Oskay-Oezcelik G, Zeimet A, Sommer H, Klare P, et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 2008; 26(19): 3176-82.

98. Mutch D, Orlando M, Goss T, Teneriello M, Gordon A, Mc-Meekin S, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007; 25(19): 2811-8.

99. Gordon A, Tonda M, Sun S, Rackoff W; Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004; 95(1): 1-8.

100. Monk B, Herzog T, Kaye S, Krasner C, Vermorken J, Muggia F, et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010; 28(19): 3107-14.

101. Gore M, ten Bokkel Huinink W, Carmichael J, Gordon A, Davidson N, Coleman R, et al. Clinical evidence for topotecanpaclitaxel non-cross-resistance in ovarian cancer. J Clin Oncol 2001; 19(7): 1893-900.

102. Garcia A, Hirte H, Fleming G, Yang D, Tsao-Wei D, Roman L, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II Consortia . J Clin Oncol 2008; 26(1): 76-82.

103. Parmar M, Ledermann J, Colombo N, du Bois A, Delaloye J, Kristensen G, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGOOVAR- 2.2 trial. Lancet 2003; 361: 2099-106.

104. Pfisterer J, Vergote I, Du Bois A, Eisenhauer E; AGO-OVAR; NCI CTG, et al. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer 2005; 15(S1): 36-41.

105. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010; 28(20):3323-9.

106. Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte H, Bryson P. On behalf of the Gynecology Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 2007; 14(5): 195-208.

107. Cervantes G. Quimioterapia de segunda línea. Cancerología 2007; 2(S1): S55-S58.

108. Bristow R, Puri I, Chi D. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 2009; 112(1): 265-74.

109. Cantú D. Cirugía citorreductora secundaria. Cancerología 2007; 2(S1): 43-6.

110. Helm C. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Oncologist 2009; 14(7): 683-94.

111. Chua T, Robertson G, Liauw W, Farrel R, Yan T, Morris D. Intraoperative hypertermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol 2009; 135(12): 1637-45.

112. Di Giorgio A, Naticchioni E, Biacchi D, Sibio S, Accarpio F, Rocco M, et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 2008; 113(2): 315-25.

113. Corn B, Lanciano R, Boente M, Hunter W, Ladazack J, Ozols R. Recurrent ovarian cancer. Effective radiotherapeutic palliation after chemotherapy failure. Cancer 1994; 74(11): 2979-83.

114. Tinger A, Waldron T, Peluso N, Katin M, Dosoretz D,Blitzer P, et al. Effective palliative radiation therapy in advanced and recurrent ovarian carcinoma. Int J Radiat Oncol Biol Phys 2001; 51 (5): 1256-63.

115. Vang R, Shih IeM, Kurman R. Ovarian low-grade and highgrade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009; 16(5): 267-82.

116. Lackman F, Carey M, Kirk M, McLachlin C, Elit L. Surgery as sole treatment for serous tumors of the ovary with noninvasive implants. Gynecol Oncol 2003; 90(2): 407-12.

117. Leake J, Currie J, Rosenshein N, Woodruff J. Long-term follow- up of serous ovarian tumors of low malignant potential. Gynecol Oncol 1992; 47(2): 150-8.

118. Camatte S, Morice P, Atallah D, Pautier P, Lhommé C, Haie- Meder C, et al. Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: an analysis of a series of 42 lymphadenectomies. J Am Coll Surg 2002; 195(3): 332-8.

119. Shepherd J. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 1989; 96(8): 889-92.

120. Ovary. In: American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002, p. 275-84.

121. Medeiros L, Rosa D, da Rosa M, Bozzetti M. Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol 2009; 142(2): 99-105.

122. Kurman R, Trimble C. The behaviour of serous tumors of low malignant potential: are they ever malignant? Int J Gynecol Pathol 1993; 12(2): 120-7.

123. Shih IeM, Kurman R. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res 2005; 11(20): 7273-9.

124. Longacre TA, Gilks CB. Surface epithelial stromal tumors of the ovary in Gynecology pathology a volume in the series of Foundations in Diagnostic Pathology. Nucci M, Oliva E (ed.). Elserviere Churchill Livingstone; 2009.

125. McCluggage G. The pathology of and controversial aspects of ovarian borderline tumors. Curr Opin Oncol 2010; 22(5): 46-72.

126. Fadare O. Recent developments on the significance and pathogenesis of lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors). Int J Gynecol Cancer 2009; 19(1): 103-8.

127. Lesieur B, Kane A, Duvillard P, Gouy S, Pautier P, Lhommé C, et al. Prognostic value of lymph node involvement in ovarian serous borderline tumors. As J Obstet Gynecol 2011.

128. Gol M, Baloglu A, Yigit S, Dogan M, Aydin C, Yensel U. Accuracy of frozen section diagnosis in ovarian tumors: Is there a change in the course of time? Int J Gynecol Cancer 2003; 13(5): 593-7.

129. Ismiil N, Ghorab Z, Nofech-Mozes S, Plotkin A, Covens A, Osborne R, et al. Intraoperative consultation in gynecologic pathology: a 6-year audit at a tertiary care medical center. Int J Gynecol Cancer 2009; 19(1): 152-7.

130. Gershenson D. Clinical management potential tumours of low malignancy. Best Pract Res Clin Onstet Gynaecol 2002; 16(4): 513-27.

131. Muzii L, Palaia I, Sansone M, Calcagno M, Plotti F, Angioli R, et al. Laparoscopic fertility-sparing stagind in unexpected early stage ovarian malignancies. Fertil Steril 2009; 91(6): 2632-7.

132. Palomba S, Zupi E, Russo T, Falbo A, Del Negro S, Manguso F, et al. Comparison of two fertility-sparing approaches for bilateral borderline ovarian tumours: a randomized controlled study. Hum Reprod 2007; 22(2): 578-85.

133. Piura B, Dgani R, Blickstein I, Yanai-Inbar I, Czernobilsky B, Glezerman M. Epithelial ovarian tumors of borderline malignancy: a study of 50 cases. Int J Gynecol Cancer 1992; 2(4): 189-97.

134. Zapardiel I, Rosenberg P, Peiretti M, Zanagnolo V, Sanguineti F, Aletti G,et al. The role of restaging borderline ovarian tumors: single institution experience and review of the literature. Gynecol Onco 2010; 119(2): 274-7.

135. Cadron I, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I. Management of borderline ovarian neoplasms. J Clin Oncol 2007; 25(20): 2928-37.

136. Tinelli R, Malzoni M, Cosentino F, Perone C, Tinelli A, Malvasi A, et al. Feasibility, safety, and efficacy of conservative laparoscopic treatment of borderline ovarian tumors. Fertil Steril 2009; 92(2): 736-41.

137. Tropé C, Kaern J, Vergote I, Kristensen G, Abeler V. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. Gynecol Oncol 1993; 51(2): 236-43.

138. Wong H, Low J, Chua Y, Busmanis I, Tay E, Ho T .Ovarian tumors of borderline malignancy: a review or 247 patients from 1991 to 2004. Int J Gynecol Cancer 2007; 17(2): 342-9.

139. Zanetta G, Rota S, Lissoni A, Meni A, Brancatelli G, Buda A. Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors. Gynecol Oncol 2001; 81(1): 63-6.

140. Vigano R, Petrone M, Pella F, Rabaiotti E, De Marzi P, Mangili G. Surgery in advanced borderline tumors. Fertil Steril 2010; 94(3): 1163-5.

141. Gilks C, Alkushi A, Yue J, Lanvin D, Ehlen T, Miller D. Advanced- stage serous borderline tumors of the ovary: a clinicopathlogic study of 49 cases. Int J Gynecol Pathol 2003; 22(1): 29-36.

142. Oosterhuis J, Looijenga L. Testicular germ-cell tumours in a broader perspective. Nat Rev Cancer 2005; 5(3): 210–22.

143. Houldsworth J, Korkola J, Bosl G, Chaganti R. Biology and genetics of adult male germ cell tumors. J Clin Oncol 2006; 24(35): 5512-8.

144. Ulbright TM. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod Pathol 2005; 18(Suppl. 2): S61-79.

145. Hoei-Hansen C, Kraggerud S, Abeler V, Kaern J, Rajpert-De Meyts E, Lothe R. Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers. Mol Cancer 2007; 6: 12.

146. Roth L, Talerman A. Recent advances in the pathology and classification of ovarian germ cell tumors. Int J Gynecol Pathol 2006; 25(4): 305-20.

147. Quirk J, Natarajan N. Ovarian cancer incidence in the United States, 1992–1999. Gynecol Oncol 2005; 97(2): 519-23.

148. You W, Dainty L, Rose G, Krivak T, McHale M, Olsen C, et al. Gynecologic malignancies in women aged less than 25 years. Obstet Gynecol 2005; 105(6): 1405-9.

149. Thomas G, Dembo A, Hacker N, DePetrillo A. Current therapy for dysgerminoma of the ovary. Obstet Gynecol 1987; 70(2): 268-75.

150. Patterson D, Rustin G. Controversies in the management of germ cell tumours of the ovary. Curr Opin Oncol 2006; 18(5): 500-6.

151. Bonazzi C, Peccatori F, Colombo N, Lucchini V, Cantù MG, Mangioni C. Pure ovarian immature teratoma, a unique and curable disease: 10 years’ experience of 32 prospectively treated patients. Obstet Gynecol 1994; 84(4): 598-604.

152. Bridgewater JA, Rustin GJ. Management of non-epithelial ovarian tumours. Oncology 1999; 57(2): 89-98.

153. Zanagnolo V, Sartori E, Galleri G, Pasinetti B, Bianchi U. Clinical review of 55 cases of malignant ovarian germ cell tumors. Eur J Gynaecol Oncol 2004; 25(3): 315-20.

154. Gershenson DM. Fertility-sparing surgery for malignancies in women. J Natl Cancer Inst Monogr 2005; (34): 43-7.

155. Billmire D, Vinocur C, Rescorla F, Cushing B, London W, Schlatter M, Davis M, Giller R, Lauer S, Olson T; Children’s Oncology Group (COG). Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg 2004; 39(3): 424-9; discussion 424-9.

156. Munkarah A, Gershenson DM, Levenback C, Silva EG, Messing MJ, Morris M, Burke TW. Salvage surgery for chemorefractory ovarian germ cell tumors. Gynecol Oncol 1994; 55(2): 217-23.

157. Looijenga LH, Stoop H, de Leeuw HP, de Gouveia Brazao CA, Gillis AJ, van Roozendaal KE, van Zoelen EJ, Weber RF, Wolffenbuttel KP, van Dekken H, Honecker F, Bokemeyer C, Perlman EJ, Schneider DT, Kononen J, Sauter G, Oosterhuis JW. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res 2003; 63(9):2244-50.

158. Cheng L, Thomas A, Roth LM, Zheng W, Michael H, Karim FW. OCT4: a novel biomarker for dysgerminoma of the ovary. Am J Surg Pathol 2004; 28(10):1341-6.

159. Sever M, Jones TD, Roth LM, Karim FW, Zheng W, Michael H, Hattab EM, Emerson RE, Baldridge LA, Cheng L. Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary: diagnostic and therapeutic implications. Mod Pathol 2005; 18(11):1411-6.

160. Lai C, Chang TC, Hsueh S, Wu T, Chao A, Chou H, Wang P. Outcome and prognostic factors in ovarian germ cell malignancies. Gynecol Oncol 2005; 96(3):784-91.

161. O’Connor DM, Norris HJ. The influence of grade on the outcome of stage I ovarian immature (malignant) teratomas and the reproducibility of grading. Int J Gynecol Pathol 1994; 13(4): 283-9.

162. Dark GG, Bower M, Newlands ES, Paradinas F, Rustin GJ. Surveillance policy for stage I ovarian germ cell tumors. J Clin Oncol 1997; 15(2): 620-4.

163. Quirk JT, Natarajan N. Ovarian cancer incidence in the United States, 1992-1999. Gynecol Oncol 2005; 97(2): 519-23.

164. Williams SD. Ovarian germ cell tumors: an update. Semin Oncol 1998; 25(3): 407-13.

165. PDQ Adult Treatment Editorial Board. Ovarian germ cell tumors (PDQ): treatment. 2004. Available from: http:// www.nci.nih.gov/cancertopics/pdq [Accesed on April 27,2006].

166. Horwich A, Sleijfer DT, Fossa SD, Kaye SB, Oliver RT, Cullen MH, Mead GM, de Wit R, de Mulder PH, Dearnaley DP, Cook PA, Sylvester RJ, Stenning SP. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997; 15(5): 1844-52.

167. Dimopoulos MA, Papadimitriou C, Hamilos G, Efstathiou E, Vlahos G, Rodolakis A, Aravantinos G, et al. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. Gynecol Oncol 2004; 95(3): 695-700.

168. Gershenson DM. Update on malignant ovarian germ cell tumors. Cancer 1993; 71(4 Suppl.): 1581-90.

169. Einhorn L, Stender M, Williams S. Phase II Trial of Gemcitabine in Refractory Germ Cell Tumors. J Clin Oncol 1999; 17(2): 509.

170. Seymour M, Mansi J, Gallagher C, Gore M, Harper P, Evans T, et al. Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer 1994; 69(1): 191-5.

171. Fayers P, Machin D. Quality of life: Assessment, analysis and interpretation. Wiley, New York, 2000.

172. Jachuk SJ, Brierly H, Jachuk S, Willcox PM. The effect of hypotensive drugs on quality of life. J R Coll Gen Pract 1982; 32: 103-5.

173. Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, du Bois A. Randomized Study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group Comparing Quality of Life in Patients With Ovarian Cancer Treated With Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel. J Clin Oncol 2006; 24: 579-86.

174. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life Instrument for use in International Clinical Trials in Oncology. J Natl Cancer Inst 1993; 85: 356-76.

175. Greimel E, Bottomley A, Cull A, Waldenstromd AC, Arraras J, Chauvenet L, et al on behalf of the EORTC Quality of Life Group and the Quality of Life Unit. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer 2003; 39: 1402-8.